On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty

Background. Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established.Aims to evaluate the impact of HBsAg kinetics before treatment interruption on post-treatment response. Methods. Longitudinal, ambispective study in non-cirrho...

Descripción completa

Detalles Bibliográficos
Autores: Broquetas, Teresa|||0000-0002-5935-3076, Hernandez, Juan-Jose, Garcia-Retortillo, M.|||0000-0001-6783-7604, Canillas, Lidia, Puigvehí, Marc|||0000-0002-3694-3241, Cañete Hidalgo, Nuria|||0000-0001-9501-7590, Coll, Susanna|||0000-0002-0395-9685, Viu, Ana, Garrido, Esther, Mico, Miquel, Bessa Caserras, Xavier|||0000-0003-4680-1228, Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:251426
Acceso en línea:https://ddd.uab.cat/record/251426
https://dx.doi.org/urn:doi:10.1016/j.dld.2021.12.017
Access Level:acceso abierto
Palabra clave:Antiviral
HBsAg
HepatitisB
Kinetics
Descripción
Sumario:Background. Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established.Aims to evaluate the impact of HBsAg kinetics before treatment interruption on post-treatment response. Methods. Longitudinal, ambispective study in non-cirrhotic chronic hepatitis B HBeAg-negative patients, analysing on-treatment and post-treatment HBsAg kinetics. On-treatment HBsAg kinetics diagnostic accuracy (AUROC) to identify HBsAg loss was evaluated. Results. 52 HBeAg-negative patients stopped treatment after 8.2 years, and 6 (11.5%) achieved HBsAg loss one year after withdrawal. Multivariate analysis showed that on-treatment HBsAg kinetics was related to HBsAg loss (OR=0.10; 95%CI=0.016-0.632; p = 0.014) with a high diagnostic accuracy (AUROC=0.935). A significant HBsAg decline ≥1 log10 IU/mL showed a positive and negative predictive value of 50% and of 97.6%, respectively. After treatment interruption, HBsAg decline speed (log10 IU/mL/year) accelerated in patients treated.

Similares en LA Referencia